XXXX agonist-triggered pathological behaviors: surveillance in the @entity191 clinic reveals high frequencies.

@entity1 @entity146 @entity935 @entity191 @entity11532
BACKGROUND: @entity146 provoked by @entity935 agonists often go undetected in clinical series, especially if not specifically inquired about. AIM: To determine the frequency of @entity146 in a @entity191 ( @entity191 ) clinic where agonist-treated @entity1 were routinely asked about such aberrant behaviors. METHODS: We utilized the Mayo Health Science Research database to ascertain all @entity191 @entity1 taking a @entity935 agonist over a two year period (2007-2009). All were seen by a Mayo-Rochester Movement Disorders Staff specialist who routinely inquired about behavior compulsions. RESULTS: Of 321 @entity191 @entity1 taking an agonist, 69 (22%) experienced @entity146 , and 50/321 (16%) were pathologic. However, when the analysis was restricted to @entity1 taking agonist doses that were at least minimally therapeutic, pathological behaviors were documented in 24%. The subtypes were: gambling (25; 36%), hypersexuality (24; 35%), compulsive spending/shopping (18; 26%), binge eating (12; 17%), compulsive hobbying (8; 12%) and compulsive computer use (6; 9%). The vast majority of affected cases (94%) were concurrently taking carbidopa/levodopa. Among those with adequate followup, behaviors completely or partly resolved when the @entity935 agonist dose was reduced or ceased. CONCLUSIONS: @entity935 agonist treatment of @entity191 carries a substantial risk of pathological behaviors. These occurred in 16% of agonist-treated @entity1 ; however, when assessing @entity1 whose dose was at least minimally in the therapeutic range, the frequency jumped to 24%. @entity11532 and hypersexuality were most common. Carbidopa/levodopa therapy taken concurrently with a @entity935 agonist appeared to be an important risk factor.
